Rule 8.1- C.A.T.

21 Jun 2006 17:11

Goldman Sachs & Co.21 June 2006 FORM 8.1 LATE DISCLOSURE DEALINGS BY OFFERORS, OFFEREE COMPANIES OR THEIR ASSOCIATES FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS (Rules 8.1(a) and (b)(i) of the City Code on Takeovers and Mergers) 1. KEY INFORMATION Name of person dealing (Note 1) Goldman Sachs & Co.Company dealt in CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLCClass of relevant security to which the Ordinary sharesdealings being disclosed relate (Note 2) Date of dealing 30 May 2006 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class ofrelevant security dealt in (Note 3) Long Short Number Number (%) (%) (1) Relevant securities 0 0 (0.00%) (0.00%) (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total 0 0 (0.00%) (0.00%) (b) Interests and short positions in relevant securities of the company,other than the class dealt in (Note 3) Class of relevant security: Long Short Number Number (%) (%) (1) Relevant securities (1) Relevant securities (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total (c) Rights to subscribe (Note 3) Class of relevant security: Details 3. DEALINGS (Note 4) (a) Purchases and sales Purchase/sale Number of securities Price per unit (Note 5) Sale * 200 24.48 USD *Goldman Sachs brought this trade to the attention of the Panel and theconsequences of this transaction are being considered. (b) Derivatives transactions (other than options) Product name, Long/short (Note 4) Number of securities (Note 5) Price per unit (Note 3) e.g. CFD (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product name, Writing, selling, Number of securities Exercise Type, e.g. Expiry Option money purchasing, to which the option American,e.g. call option varying etc. relates (Note 7) price European etc. date paid/received per unit (Note 5) (ii) ExercisingProduct name, e.g. call option Number of securities Exercise price per unit (Note 5) (d) Other dealings (including new securities) (Note 4) Nature of transaction (Note 8) Details Price per unit (if applicable) (Note 5) 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relatingto the voting rights of any relevant securities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form isreferenced. If none, this should be stated. None Is a Supplemental Form 8 attached? (Note 9) NO Date of disclosure 21 June 2006 Contact name Peter Highton Telephone number +44-207-774-1935 Name of offeree/offeror with which associated AstrazenecaSpecify category and nature of associate status (Note 10) Adviser Notes The Notes on Form 8.1 can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange